olaparib,abiraterone
astrazeneca,merck
['crpc', 'abira', 'olaparib', 'propel', 'abiraterone', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)']
final analysis of propel supports abiraterone/olaparib as first-line option in mcrpc #urology #urologist #gu23
The Leading News Source for Urologists - https://t.co/hDKngB4IyE
Expert clinical analysis. Practice advice. Policy perspectives.